- VitriVax has received a $9.9 million, two-year grant from the Gates Foundation to scale up its Atomic Layering Thermostable Antigen and Adjuvant (ALTA) vaccine technology.
- The funding will enable GMP manufacturing readiness and support collaboration with a CDMO for early-phase clinical production.
VitriVax, Inc., a vaccine formulation technology company, has been awarded a two-year, $9.9 million grant from the Gates Foundation. The funding will support the scale-up of the company’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA) platform and prepare it for Phase 1 clinical trials.
As part of the grant, VitriVax will collaborate with a Contract Development and Manufacturing Organization (CDMO) to conduct early-phase clinical manufacturing. The project includes preparing and executing manufacturing and regulatory activities required for the future development of an ALTA-enabled vaccine.
The ALTA technology is designed to stabilise antigens and adjuvants, allowing the co-formulation of components that are typically incompatible. This approach aims to enhance vaccine compatibility, utility, and supply resilience. Scaling up the ALTA platform will help de-risk early manufacturing processes and accelerate the path from formulation to first-in-human studies.
“This grant enables us to take ALTA from lab-scale innovation to Phase 1-ready GMP manufacturing, an essential step toward broader access to next-generation vaccines. By working with a CDMO partner, we are not only preparing for first-in-human clinical studies but also laying the groundwork for scalable, reliable production that supports global public health priorities.”
Romulo Colindres, Chief Executive Officer of VitriVax
